Synexo Group (SYNEXO) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
21 Aug, 2025Executive summary
Divested entire stake in loss-making former subsidiary LC-Tec Future Innovations AB, leaving only a cash position of approximately SEK 3 million after the sale.
Ongoing negotiations to acquire a Norwegian group providing data storage-related services, with a conditional agreement in place.
No operating business or revenue-generating activities remain after the divestment; the company is currently a pure investment entity.
Board and management changes occurred in May 2025, including a new CEO and board members.
Financial highlights
Net sales for H1 2025 were SEK 450,000, down from SEK 1,375,000 in H1 2024.
Operating result for H1 2025 was SEK -93,000, compared to SEK 356,000 in H1 2024.
Result after financial items for H1 2025 was SEK -14,029,000, a significant decline from SEK 24,000 in H1 2024.
Cash flow from operating activities was SEK 1,447,000 in H1 2025, compared to SEK -10,053,200 in H1 2024.
Equity as of June 30, 2025, stood at SEK 644,000, down from SEK 1,680,000 a year earlier.
Outlook and guidance
Management expresses a positive outlook for the remainder of 2025, contingent on the successful acquisition of the Norwegian data storage group.
An extraordinary general meeting is scheduled for September 12, 2025, to potentially approve a directed share issue related to the acquisition.
Latest events from Synexo Group
- ARR up 61% y/y, strong upsell, low churn, and M&A activity drive growth and margin targets.SYNEXO
Q4 202526 Feb 2026 - Strong organic growth, high margins, and disciplined M&A drive scalable, shareholder-focused value.SYNEXO
Investor Presentation2 Jan 2026 - Q3 2025 delivered 56% pro forma revenue growth, 63% gross margin, and strong ARR expansion.SYNEXO
Q3 202528 Nov 2025 - Sales dropped sharply and losses deepened, with recovery delayed to 2025/2026.SYNEXO
Q3 202413 Jun 2025 - Net sales dropped 43.6% and a SEK 2.6 million order was secured from Pathogen Systems Inc.SYNEXO
Q2 202413 Jun 2025 - Sales up, losses persist; MedTech order and new partnerships drive future focus.SYNEXO
Q1 20256 Jun 2025 - Omsättning föll 39% och fortsatt förlust kräver ny finansiering och omstrukturering.SYNEXO
Q4 20245 Jun 2025